Symptomatic Control of Neuroendocrine Tumours with Everolimus (Q40657042)

22 September 2017

Symptomatic Control of Neuroendocrine Tumours with Everolimus (English)

1 reference

22 September 2017

Hannah E Bainbridge

1

1 reference

PubMed ID

26245686

22 September 2017

Emmanuel Larbi

series ordinal

2

1 reference

PubMed ID

26245686

22 September 2017

Gary Middleton

series ordinal

3

1 reference

22 September 2017

6 August 2015

1 reference

22 September 2017

1 reference

22 September 2017

6

1 reference

22 September 2017

254-259

1 reference

22 September 2017

5-6

1 reference

https://scigraph.springernature.com/pub.10.1007/s12672-015-0233-2

22 September 2017

0 references

cites work

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Current knowledge on diagnosis and staging of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

Control of carcinoid syndrome with everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-015-0233-2

10.1007/S12672-015-0233-2

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

26245686